Browse EX-10 agreements

Corrected Version from that filed as Exhibit 10.1 to the Form 8-K on June 10, 2026

CONTRIBUTION AGREEMENT

by and among

WhiteHawk Income Corporation, a Delaware corporation,

WhiteHawk Income Operating Partnership L.P.,a Delaware limited partnership,

WhiteHawk Management LLC, a Delaware limited liability company,

and

WhiteHawk Minerals LLC, a Delaware limited liability company,

dated as of

June 9, 2026

---

TABLE OF CONTENTS

Page

…

2000 Market St., Suite 910

Philadelphia, PA 19103

Form of Equity Commitment Letter

August 12, 2026

WhiteHawk Minerals Corp.

2000 Market Street, Suite 910
Philadelphia, PA 19103

Re: Commitment to Purchase Series E Preferred Equity

Ladies and Gentlemen:

This Equity Commitment Letter (this “Commitment Letter”) sets forth the agreement of [INVESTOR] (“Investor”) to purchase preferred equity of WhiteHawk Minerals Corp. (the “Company”), on the terms described below.

1.

Commitment

Subject to the terms and conditions set forth herein, Investor hereby irrevocably commits to purchase $[AMOUNT] (the “Commitment”) of the Company’s Series E Preferred Stock for a price of $1,000 per share (the “Series E Preferred Equity”), pursuant to the terms of the Company’s governing documents and the definitive purchase agreement to be entered into in connection therewith.

2.

Funding

…

AMENDMENT NO. 2

TO

FLUENT, INC.
2022 OMNIBUS EQUITY INCENTIVE PLAN

Fluent, Inc., a Delaware corporation (the “Company”), hereby amends its 2022 Omnibus Equity Incentive Plan (the “Plan”) as set forth below, which amendments shall be effective as of the date set forth below.

Section 4(a) of the Plan shall be amended and restated in its entirety to read:

(a) Subject to Section 5 hereof, the maximum number of shares of Common Stock that are reserved and available for issuance pursuant to Awards granted under the Plan shall be equal to the sum of (i) 5,566,666 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2018 Plan; provided, that, shares of Common Stock issued under the Plan with respect to an Exempt Award shall not count against such share limit. Following the Effective Date, no further awards shall be issued under the Prior Plans, but all awards under the Prior Plans which are outstanding as of the Effective Date (including any Grandfathered Arrangement) shall continue to be governed by the terms, conditions and p

…

FLUENT, INC. 
RESTRICTED STOCK UNIT AWARD GRANT NOTICE 
(2022 Omnibus Equity Incentive Plan)

As a key contributor in our business, you are in a position to have significant influence on the performance and success of Fluent, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted a Restricted Stock Unit Award. This award is subject to the terms and conditions of the Fluent, Inc. 2022 Omnibus Equity Incentive Plan, this Grant Notice, and the following Restricted Stock Unit Agreement. The details of this award are indicated below.

…

WAIVER AGREEMENT

This Waiver Agreement (the “Agreement”) is made on this 12thday of August 2026, by and between MidCap Apollo Institutional Private Lending (the “Company”) and Apollo Credit Management, LLC, the Company’s investment adviser (the “Adviser”). Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Advisory Agreement (as defined below).

WITNESSETH:

WHEREAS, the Company is a closed-end, non-diversified management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the “1940 Act”);

WHEREAS, the Company and the Adviser entered into that certain Investment Advisory Agreement, dated March 15, 2024, by and between the Company and the Adviser (the “Advisory Agreement”), pursuant to which the Adviser provides investment advisory services to the Company; and

…

STANDBY EQUITY PURCHASE AGREEMENT

** **

THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of August 12, 2026 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and **HEALTH IN TECH, INC., **a company incorporated under the laws of the State of Nevada (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collectively as the “Parties.”

** **

WHEREAS, the Parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to $20 million of the Company’s shares of Class A common stock, par value $0.001 per share (the “Common Shares”);

** **

WHEREAS, the Common Shares are listed for trading on the Nasdaq Stock Market under the symbol “HIT;”

** **

…

GLOBAL GUARANTY AGREEMENT

This Guaranty (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Guaranty”) is made as of August __, 2026, by the entities listed on Schedule I attached hereto and any subsequent party that may join in this Guaranty (collectively, the “Guarantors”) in favor of YA II PN, LTD. (“YA II” or the “Creditor”), with respect to all obligations of HEALTH IN TECH, INC., a Nevada corporation (the “Debtor”) owed to the Creditor.

** **

RECITALS

WHEREAS, the Creditor and the Debtor have entered into a Standby Equity Purchase Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Agreement”) dated as of August 12, 2026, pursuant to which the Creditor shall provide advances to the Debtor (the “Pre-Paid Advances”) to be evidenced by promissory notes issued to the Creditor (the “Promissory Notes”), pursuant to and upon the terms and conditions of the Agreement, in the aggregate amount of up to $15,000,000;

** **

…

REGISTRATION RIGHTS AGREEMENT

** **

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) dated as of August __, 2026, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and HEALTH IN TECH, INC., a company incorporated under the laws of the State of Nevada (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collectively as the “Parties.”

** **

WHEREAS, the Company and the Investor have entered into that certain Standby Equity Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Company may issue, from time to time, to the Investor up to $20 million of newly issued shares of the Company’s shares of Class A Common Stock, par value $0.001 per share (the “Common Shares”); and

** **

…

PURCHASE AGREEMENT

between

FireFish TopCo, LLC

and

Aspire Biopharma Holdings, Inc.

Dated as of June 10, 2026

TABLE OF CONTENTS

Article I DEFINITIONS AND INTERPRETATIONS			1
	Section 1.01.	Definitions	1

…

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES

Original Issue Date: __________________

Original Principal Amount: $___________________

20% ORIGINAL ISSUE DISCOUNT

SENIOR SECURED CONVERTIBLE

DEBENTURE

DUE *                  * 20261

…

Independent Director Agreement

This agreement (the “Agreement”) is made effective as of August 12, 2026 by BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), and Susan E. Atkins (the “Director”).

WHEREAS, the Director is to be elected to the Company’s Board of Directors (the “Board”) pursuant to the By-Laws of the Company (the “Bylaws”) and the Company’s Amended and Restated Certification of Incorporation (as amended, the “Certification of Incorporation”);

WHEREAS, this Agreement is supplemental to and in furtherance of the Bylaws, the Certificate of Incorporation, and any resolutions adopted pursuant thereto and shall not be deemed a substitute thereof, nor diminish or abrogate the rights thereunder;

WHEREAS, the Director is willing to provide services to the Board on the terms and conditions set forth in this Agreement;

WHEREAS, the Company has spent significant time, effort and money to develop certain Confidential Information, which the Company considers vital to its business and goodwill;

…

​

BIOXCEL THERAPEUTICS, INC.

INDEMNIFICATION AGREEMENT

This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of August 12, 2026 by and between BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), and Susan Atkins (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.

RECITALS

WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

…